Stock Events

Stock Events

Damora Therapeutics 

$25.5
0
-$0.4-1.54% Today

Statistics

Day High
26.72
Day Low
25.45
52W High
38.33
52W Low
2.01
Volume
8,771
Avg. Volume
237,762
Mkt Cap
33.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24AprExpected
Q3 2025
Next
-2.36
-1.67
-0.99
-0.3
Expected EPS
-0.300355
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.88MNet Income

Analyst Ratings

$44.25Average Price Target
The highest estimate is 46.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV specializes in drug discovery for fibrosis and other indications, overlapping with Galecto's research areas.
ProQR Therapeutics N.V
PRQR
Mkt Cap289.7M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap237.61B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Show more...
CEO
Dr. Hans T. Schambye M.D., Ph.D.
Employees
5
Country
US
ISIN
US36322Q2066

Listings

XNAS
US
GLTO
BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Damora Therapeutics stock price today?▼
The current price of DMRA is $25.5 USD — it has decreased by -1.54% in the past 24 hours. Watch Damora Therapeutics stock price performance more closely on the chart.
What is Damora Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Damora Therapeutics stocks are traded under the ticker DMRA.
What is Damora Therapeutics market cap?▼
Today Damora Therapeutics has the market capitalization of 33.84M
When is the next Damora Therapeutics earnings date?▼
Damora Therapeutics is going to release the next earnings report on April 24, 2026.
What were Damora Therapeutics earnings last quarter?▼
DMRA earnings for the last quarter are -2.36 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Damora Therapeutics revenue for the last year?▼
Damora Therapeutics revenue for the last year amounts to 0 USD.
What is Damora Therapeutics net income for the last year?▼
DMRA net income for the last year is -42.88M USD.
How many employees does Damora Therapeutics have?▼
As of April 01, 2026, the company has 5 employees.
In which sector is Damora Therapeutics located?▼
Damora Therapeutics operates in the Health Care sector.
When did Damora Therapeutics complete a stock split?▼
Damora Therapeutics has not had any recent stock splits.
Where is Damora Therapeutics headquartered?▼
Damora Therapeutics is headquartered in Copenhagen, US.